OBJECTIVE: The present study aimed to evaluate the profile of patients with decompensated heart failure hospitalized in a tertiary hospital. METHODS: It was designed an observational and retrospective study where data from clinical records of patients suffering from heart failure along 2005 were registered randomly. RESULTS: 209 patients were collected (average age: 78.6 +/- 9.1; male: 52.4%) with a comorbidity rate of 87.55%. Almost one third of them have not stimation of systolic function and among the others 72.4% have it preserved. Most of decompensated were due to respiratory infections. Ischemic-hipertensive cardiopathy was the most frequent aetiology of systolic disfunction. Average stay was 12.9 days with a mortality rate of 9.56%. Its main risk factors were advanced stages in NYHA od Red Cross scales, as so as dementia or ictus. CONCLUSIONS: The present study shows a patient hospitalized for decompensated heart failure roughly different from that one reported at clinical trials. It makes difficult to apply therapeutical interventions, previously well documented to be useful.
OBJECTIVE: The present study aimed to evaluate the profile of patients with decompensated heart failure hospitalized in a tertiary hospital. METHODS: It was designed an observational and retrospective study where data from clinical records of patients suffering from heart failure along 2005 were registered randomly. RESULTS: 209 patients were collected (average age: 78.6 +/- 9.1; male: 52.4%) with a comorbidity rate of 87.55%. Almost one third of them have not stimation of systolic function and among the others 72.4% have it preserved. Most of decompensated were due to respiratory infections. Ischemic-hipertensive cardiopathy was the most frequent aetiology of systolic disfunction. Average stay was 12.9 days with a mortality rate of 9.56%. Its main risk factors were advanced stages in NYHA od Red Cross scales, as so as dementia or ictus. CONCLUSIONS: The present study shows a patient hospitalized for decompensated heart failure roughly different from that one reported at clinical trials. It makes difficult to apply therapeutical interventions, previously well documented to be useful.
Authors: Òscar Miró; Koji Takagi; Étienne Gayat; Víctor Gil; Pere Llorens; Francisco J Martín-Sánchez; Javier Jacob; Pablo Herrero-Puente; Rosa Escoda; María Pilar López-Díez; Amparo Valero; Marta Fuentes; José M Garrido; Eva Salvo; Miguel A Rizzi; Alfons Aguirre; Lissete Travería Bécquer; Alberto Domínguez-Rodríguez; Joan Padrosa; Gemma Martínez; Mattia Arrigo; Yonathan Freund; Alexandre Mebazaa Journal: Clin Res Cardiol Date: 2019-04-29 Impact factor: 5.460
Authors: A Salinas-Botrán; J Sanz-Cánovas; J Pérez-Somarriba; L M Pérez-Belmonte; L Cobos-Palacios; M Rubio-Rivas; S de-Cossío-Tejido; J M Ramos-Rincón; M Méndez-Bailón; R Gómez-Huelgas Journal: Rev Clin Esp (Barc) Date: 2021-10-08
Authors: A Salinas-Botrán; J Sanz-Cánovas; J Pérez-Somarriba; L M Pérez-Belmonte; L Cobos-Palacios; M Rubio-Rivas; S de-Cossío-Tejido; J M Ramos-Rincón; M Méndez-Bailón; R Gómez-Huelgas Journal: Rev Clin Esp Date: 2021-07-17 Impact factor: 3.064